Vanguard Fiduciary Trust
VKTX icon

Vanguard Fiduciary Trust’s Viking Therapeutics VKTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.6M Buy
732,047
+21,635
+3% +$699K 0.01% 1196
2026
Q1 		$23.1M Buy
+710,412
New +$22.8M 0.01% 1237

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Fiduciary Trust's VKTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Viking Therapeutics (VKTX) stake by 3% in Q2 2026, buying an estimated $699K and bringing the position to 732,047 shares worth $28.6M. The position accounts for 0.01% of the portfolio, ranked #1196.

Vanguard Fiduciary Trust first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 431 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 732,047 shares of Viking Therapeutics worth $28.6M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 21,635 Viking Therapeutics shares in Q2 2026, an estimated $699K.
  • Viking Therapeutics made up 0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #1196 holding.
  • Vanguard Fiduciary Trust first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 431 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.